peptide half-life raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-17. Anything still debated is marked as such rather than presented as settled.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Angiofibroma (AGF) is a descriptive term for a wide range of benign skin or mucous membrane (i.e. the outer membrane lining body cavities such as the mouth and nose) lesions in which individuals have:
Gabapentin, sold under the brand name Neurontin among others, is an anticonvulsant medication used to treat neuropathic pain (postherpetic neuralgia) and partial seizures of epilepsy. Gabapentin is a central nervous system (CNS) depressant and derivative of the inhibitory neurotransmitter, GABA. It is used for the treatment of neuropathic pain caused by diabetic neuropathy, postherpetic neuralgia, and central pain. It is moderately effective: about 30–40% of those given gabapentin for diabetic neuropathy or postherpetic neuralgia have a meaningful benefit. Gabapentin binds to α2δ subunits to modulate calcium channel function and neurotransmitter release, weakly affects glutamate signaling pathways, and does not act on GABA receptors. Sleepiness and dizziness are the most common side effects. Serious side effects include extreme sedation, respiratory depression and allergic reactions. In December 2008, the US Food and Drug Administration issued a class-wide warning for gabapentinoids for an increased risk of suicide. Approximately two years after this pronouncement, a pharmacoepidemiologic study was conducted that showed there was no outstanding difference in suicide attempt rates between pre- and post-gabapentin prescription groups. Gabapentin was first approved for use in the United Kingdom in 1993. It has been available as a generic medication in the United States since 2004. It is the first of several other drugs that are similar in structure and mechanism, called gabapentinoids.
The French naturalist Georges-Louis Leclerc (1707–1788) underlined the benefits of donkey milk in his Histoire Naturelle. Some effects have been supported by systematic and scientific studies starting from the mid-1800s, especially by Russian doctors. Donkey and mare's milk are very similar, and it is assumed they have similar properties. The beneficial effects of equid milk, from the first historical sources to the present day, are aimed at:
1994: Ong Yeow Tian, a Singaporean hairstylist who was hanged on 25 November 1994 for murdering a police officer and shooting two other cops in 1989. 1995: Ng Theng Shuang, a Malaysian national, hanged on 14 July 1995 for discharging a firearm with intent to cause injury, after shooting 3 people during the attempted robbery of Tin Sing Goldsmiths in South Bridge Road in 1992. 1997: Lim Chwee Soon, hanged on 25 July 1997 for discharging a firearm seven times during the robbery of the Kee Hing Hung Rolex boutique at the People's Park Complex in 1995. 2001: Tay Chin Wah, a Singaporean taxi driver, was arrested for an unsolved 1995 case of shooting two men. He was sentenced to death on 21 February 2001, and hanged on 26 October 2001. 2006: Khor Kok Soon, one of Singapore's top ten fugitives, was charged in 2004 for firing a gun at 43-year-old police sergeant Lim Kiah Chin (who escaped unharmed) in 1984. He was sentenced to death in February 2005, and eventually hanged. Khor was also alleged to have killed 25-year-old truck driver Ong King Hock. 2006: Lim Thian Lai, a Singaporean gunman who was caught in 2004 for murdering an illegal moneylender Tan Tiong Huat back in 1997. Lim was found guilty of discharging a firearm and killing Tan by shooting, and sentenced to death in May 2005. He lost his appeal in September 2005 and had since been hanged. 2009: Tan Chor Jin, alias Tony Kia, nicknamed the "One-eyed Dragon" in Singapore media, was executed on 9 January 2009 for illegally discharging a firearm and killing 41-year-old nightclub owner Lim Hock Soon by shooting.
However, a 2019 Cochrane review comparing effects of adding oxandrolone to growth hormone treatment to growth hormone alone found moderate-quality evidence that the addition of oxandrolone led to an increase in final adult height of girls with Turner syndrome, and low-quality evidence showed no increase in adverse effects. When the same review assessed the effects of adding oxandrolone to growth hormone treatment on speech, cognition and psychological status, the results were inconclusive due to very-low quality evidence. Children with idiopathic short stature or Turner syndrome were given doses of oxandrolone far smaller than those given to people with burns. Oxandrolone shows positive effects on cardiometabolic health and visual, motor, and psychosocial functions in adolescent males with preserved testosterone production, such as those with Klinefelter syndrome.
Sources: en.wikipedia.org
=== Plastics pollution === Named as one of the top five plastic polluters in Canada in 2018 and 2019; in 2019, Tim Hortons accounted for about 11% of branded plastic waste collected by Greenpeace Canada from rivers and beaches. In late 2018 and early 2019, Tim Hortons was subject to controversy over their usage of plastic cups. An online Change.org petition asking the company to switch from plastic cups to "a fully recyclable and compostable alternative" gained over 171,000 signatures. The cups were not compostable, due to their plastic lining, and are often very difficult to recycle. As of February 2019, Tim Hortons had not responded to the petition's requests. In some BC communities, recycling services accept Tim Hortons coffee cups. The City of Toronto announced in 2024 that it is piloting recycling coffee cups. In early 2020, it gave away reusable cups for its "Roll Up the Rim to Win" promotion to eliminate single-use plastic in its establishments. The effort was criticized as greenwashing through a limited-time promotion.
Trump reinstated his "maximum pressure" campaign against Iran and sought a new set of negotiations to limit Iran's nuclear program. In March 2025, Trump sent a letter to Iranian supreme leader Ali Khamenei urging new negotiations and warning of military action if talks fail. On June 13, 2025, Israeli planes bombed sites in Iran associated with Iran's nuclear program. President Trump stated he was not involved, although Iranian leaders have said they do not believe this. There have been reports that Trump vetoed a plan to kill Iran's Ayatollah Khamenei, and that the United States communicated to Israel that Iran has not killed an American and discussions of killing political leaders should not be on the table. On June 21, 2025, the U.S. attacked three nuclear sites: the Fordow uranium enrichment facility, the Natanz nuclear facility, and Isfahan nuclear technology center. B-2 airplanes took off from the state of Missouri and made the 18-hour flight to Iran, being refueled multiple times en route. Entering Iranian airspace, fighter jets cleared space ahead of them, and a Navy sub fired more than 24 Tomahawk missiles. The leading B-2 dropped two Massive Ordnance Penetrators bombs (MOPs, or "bunker-busters") at the Fordo site. A total of 14 MOPs were dropped at two target sites.
Conduct distinctive, laboratory, clinical, behavioral, translational and population-based research that breaks new ground and defines scientific excellence Facilitate new approaches to improve health through prevention, early detection, diagnosis, and treatment by developing and/or using innovative technologies, approaches or devices Respond rapidly to critical public health needs Train the next generation of biomedical and behavioral researchers Foster sharing of information and dissemination of the IRP's major discoveries to the public through partnerships with academic institutions and industry
In 2012, an alternative synthesis of the bottromycin macrocyclic ring system and amidine linkage was reported. The synthesis was achieved in 10 steps. Unlike the previous synthesis, Ackerman and colleagues synthesized a linear peptide and achieved intramolecular amidine formation using an S-methylated endothiopeptide. The endothiopeptide was obtained by a thio-Ugi reaction. The resulting macrocycle was obtained as a racemic mixture at the amidine linkage. The full synthetic scheme may be viewed under the collapsed synthetic scheme link.
== Later life and legacy == Ramachandran was devastated by the death of his wife Rajalakshmi in 1998 and his health gradually deteriorated. During the last few years of his life, he suffered a stroke and was affected by Parkinson's disease. Ramachandran died on 7 April 2001, aged 78, in Chennai. Each year, the Council of Scientific and Industrial Research (CSIR) awards the "G N Ramachandran Gold Medal for Excellence in Biological Sciences & Technology" in his memory for work in Biological Sciences & Technology.
Sources: en.wikipedia.org
===== Type 2B ===== This is a "gain of function" defect. The ability of the qualitatively defective VWF to bind to glycoprotein Ib (GPIb) receptor on the platelet membrane is abnormally enhanced, leading to its spontaneous binding to platelets and subsequent rapid clearance of the bound platelets and of the large VWF multimers. Thrombocytopenia may occur. Large VWF multimers are reduced or absent from the circulation. The ristocetin cofactor activity is low when the patient's platelet-poor plasma is assayed against formalin-fixed, normal donor platelets. However, when the assay is performed with the patient's own platelets (platelet-rich plasma), a lower-than-normal amount of ristocetin causes aggregation to occur. This is due to the large VWF multimers remaining bound to the patient's platelets. Patients with this subtype are unable to use desmopressin as a treatment for bleeding, because it can lead to unwanted platelet aggregation and aggravation of thrombocytopenia.
The mechanisms on the micellization at equilibrium have shown to depend on two relaxation times: (1) the first and fastest (tens of the microseconds scale) corresponds to the unimers exchange between micelles and the bulk solution and follows the Aniansson-Wall model (step-by-step insertion and expulsion of single polymer chains), and (2) the second and much slower one (in the millisecond range) is attributed to the formation and breakdown of whole micellar units leading to the final micellar size equilibration. Besides spherical micelles, elongated or worm-like micelles can also be formed. The final geometry will depend on the entropy costs of stretching the blocks, which is directly related to their composition (size and polyoxypropylene/polyoxyethylene ratio). The mechanisms involved in the shape transformation are different compared to the dynamics of micellization. Two mechanisms were proposed for the sphere-to-rod transitions of block copolymer micelles, in which the micellar growth can occur by (A) fusion/fragmentation of micelles or (B) concomitant fusion/fragmentation of micelles and unimer exchange, followed by smoothing of the rod-like structures. With higher increments of the temperature and/or concentration, other phenomena can occur such as the formation of highly ordered mesophases (cubic, hexagonal and lamellar). Eventually, a complete dehydration of the polyoxypropylene blocks and the collapse of the polyoxyethylene chains will lead to clouding and/or macroscopic phase separation.
=== Economics === Trastuzumab costs about US$70,000 for a full course of treatment. Australia has negotiated a lower price of A$50,000 per course of treatment. Since October 2006, trastuzumab has been made available for Australian women and men with early-stage breast cancer via the Pharmaceutical Benefits Scheme. This is estimated to cost the country over A$470 million for 4–5 years supply of the drug. Roche has agreed with Emcure in India to make an affordable version of this cancer drug available to the Indian market. Roche has changed the brand name of the drug and has re-introduced an affordable version of the same in the Indian market. The new drug named Herclon would cost approximately RS75,000 INR (US$ 870) in the Indian market. On 16 September 2014, Genentech notified hospitals in the United States that, as of October, trastuzumab could only be purchased through their selected specialty drugs distributors not through the usual general line wholesalers. By being forced to purchase through specialty pharmacies, hospitals lost rebates from the big wholesalers and the ability to negotiate cost-minus discounts with their wholesalers.
=== Mechanisms === Although the mechanisms by which BMAA causes motor neuron dysfunction and death are not entirely understood, current research suggests that there are multiple mechanisms of action. Acutely, BMAA can act as an excitotoxin on glutamate receptors, such as NMDA, calcium-dependent AMPA, and kainate receptors. The activation of the metabotropic glutamate receptor 5 is believed to induce oxidative stress in the neuron by depletion of glutathione. BMAA can be misincorporated into nascent proteins in place of L-serine, possibly causing protein misfolding and aggregation, both hallmarks of tangle diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), and Lewy body disease. In vitro research has shown that protein association of BMAA may be inhibited in the presence of excess L-serine.
Pure boron is a shiny, silver-grey crystalline solid. It is less dense than aluminium (2.34 vs. 2.70 g/cm3), and is hard and brittle. It is barely reactive under normal conditions, except for attack by fluorine, and has a melting point of 2076 °C (cf. steel ~1370 °C). Boron is a semiconductor; its room temperature electrical conductivity is 1.5 × 10−6 S•cm−1 (about 200 times less than that of tap water) and it has a band gap of about 1.56 eV. Mendeleev commented that, "Boron appears in a free state in several forms which are intermediate between the metals and the nonmmetals." The structural chemistry of boron is dominated by its small atomic size, and relatively high ionization energy. With only three valence electrons per boron atom, simple covalent bonding cannot fulfil the octet rule. Metallic bonding is the usual result among the heavier congeners of boron but this generally requires low ionization energies. Instead, because of its small size and high ionization energies, the basic structural unit of boron (and nearly all of its allotropes) is the icosahedral B12 cluster. Of the 36 electrons associated with 12 boron atoms, 26 reside in 13 delocalized molecular orbitals; the other 10 electrons are used to form two- and three-centre covalent bonds between icosahedra. The same motif can be seen, as are deltahedral variants or fragments, in metal borides and hydride derivatives, and in some halides. The bonding in boron has been described as being characteristic of behaviour intermediate between metals and nonmetallic covalent network solids (such as diamond).
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.